Peptide LibraryOvagen
Also known as: Liver/ovary bioregulator, Glu-Asp-Leu
Ovagen (also called Liver/ovary bioregulator or Glu-Asp-Leu) is a khavinson bioregulator. Ovagen is described either as the synthetic tripeptide Glu-Asp-Leu (EDL) or as a peptide complex from animal tissue. Indexed work on EDL reports effects on ageing markers in kidney cell culture and on kidney function in old rats; no study has tested a liver or ovary outcome.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Liver / ovary (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 6
- Listed offers
- 8
- Median price per mg
- $3.25/mg
- Typical $3.00–$3.25/mg
Research summary
Ovagen is sold in the Khavinson bioregulator tradition as a liver or ovary bioregulator. Product descriptions give it either as the tripeptide Glu-Asp-Leu (EDL) or as a tissue-derived peptide complex, and no indexed paper settles which. The only indexed EDL work is in cell culture and rats. No controlled human evidence exists and it is not FDA-approved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies1 reviewed source
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Ovagen profile summarises 2 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Ovagen dosage: no established human dose
Ovagen has no established human dosage. It is described as a liver or ovary bioregulator, and the profile lists the sequence Glu-Asp-Leu (EDL). No human study of Ovagen or EDL is indexed in PubMed or registered on ClinicalTrials.gov; the only indexed work on EDL is in cell culture.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Ovagen is sold in the Khavinson bioregulator tradition. The profile lists the tripeptide Glu-Asp-Leu (EDL), while some descriptions call it a tissue extract, so what a given product contains is not settled by any indexed source. The only indexed EDL study is in kidney cell culture and tests no liver or ovary outcome. No animal or human dosing study exists, so nothing here establishes a human dose, route or interval.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| In vitro — AED and EDL in ageing kidney cell culture (2014)Preclinical · Cell-culture and modelling study | Young and ageing renal cell cultures | Not stated in the indexed abstract; added to cell culture, not given to an organism | In vitro, added to culture | — | — | More cell proliferation, lower p16, p21 and p53 and higher SIRT-6 expression; modelling of EDL binding to DNA | Tripeptides slow down aging process in renal cell culture. Adv Gerontol. 2014. |
Where sources disagree
- No indexed study or registered trial reports a dose of Ovagen or EDL, so protocols given for it have no verifiable primary source.
- "Ovagen" is also the name of a veterinary follicle-stimulating hormone product used to superovulate goats, sheep and cattle. Most PubMed results for the name concern that product, not the peptide.
- Sources disagree on whether Ovagen targets the liver or the ovary; neither has been tested in an indexed study.
Reconstitution
Common research vial sizes: 20 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 20 mg | 2 mL | 10 mg/mL | 100 mcg per 0.01 mL |
| 20 mg | 4 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Sequence & molecular data
| Appearance | White lyophilized powder |
|---|---|
| Formulation | Lyophilized Powder |
| PubChem CID | 444128 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Ovagen is described either as the synthetic tripeptide Glu-Asp-Leu (EDL) or as a peptide complex from animal tissue. Indexed work on EDL reports effects on ageing markers in kidney cell culture and on kidney function in old rats; no study has tested a liver or ovary outcome. The proposed mechanism for the series is that short peptides act on gene expression in the nucleus, but no receptor or pathway has been identified for EDL.
Origin
Synthetic tripeptide (EDL) or tissue-derived complex, depending on the product.
Targets
Studies
Research statistics
19 PubMed publications · 10.5% human clinical research · 0 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Ovagen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Ovagen side effects
Ovagen has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Not characterized
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Ovagen: frequently asked questions
What is Ovagen?
Peptide preparation sold in the Khavinson bioregulator tradition, supplied as a complex of low-molecular-weight peptides extracted from animal tissue rather than a single characterised compound. Sources disagree on which organ it is intended to support, which is itself a reason for caution when interpreting product claims. No controlled human evidence exists and it is not FDA-approved.
How does Ovagen work?
Ovagen is a peptide preparation marketed in the Khavinson tradition, supplied as a complex of low-molecular-weight peptides extracted from animal tissue rather than as a single defined molecule. Because it is a mixture, no specific sequence, receptor or downstream pathway can be assigned, and the composition is not standardised between batches.
Is Ovagen FDA approved?
No. Ovagen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What peptides are similar to Ovagen?
Compounds most often compared with Ovagen include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4
This Ovagen profile is compiled from published literature (2 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Ovagen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →